ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee.

[1]  P. Ascierto,et al.  Abstract CT012: Evaluation of atezolizumab (A), cobimetinib (C), and vemurafenib (V) in previously untreated patients withBRAFV600mutation-positive advanced melanoma: Primary results from the phase 3 IMspire150 trial , 2020 .

[2]  P. Ascierto,et al.  Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  M. Mandalà,et al.  The impact of targeted therapies and immunotherapy in melanoma brain metastases: A systematic review and meta‐analysis , 2019, Cancer.

[4]  R. Scolyer,et al.  Adjuvant Whole-Brain Radiation Therapy Compared With Observation After Local Treatment of Melanoma Brain Metastases: A Multicenter, Randomized Phase III Trial. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  C. Brock,et al.  Association of Prior Antibiotic Treatment With Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients With Cancer. , 2019, JAMA oncology.

[6]  Y. Zakharia,et al.  Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events , 2019, Journal of oncology.

[7]  J. Larkin,et al.  Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. , 2019, The Lancet. Oncology.

[8]  C. Verschraegen,et al.  Effect of concomitant medications on overall survival in patients with cancer undergoing immunotherapy. , 2019, Journal of Clinical Oncology.

[9]  R. Dummer,et al.  Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma. , 2019 .

[10]  Douglas B. Johnson,et al.  Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodies , 2019, Pigment cell & melanoma research.

[11]  A. Hauschild,et al.  Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. , 2019, The New England journal of medicine.

[12]  R. Sullivan,et al.  Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients , 2019, Nature Medicine.

[13]  P. Ascierto,et al.  Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma , 2019, Nature Medicine.

[14]  R. Fisher,et al.  Combined BRAF and MEK inhibition with PD-1 blockade immunotherapy in BRAF-mutant melanoma , 2019, Nature Medicine.

[15]  M. Atkins,et al.  Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204). , 2019, Journal of Clinical Oncology.

[16]  J. Wolchok,et al.  Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. , 2019 .

[17]  J. Utikal,et al.  Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases. , 2019, European journal of cancer.

[18]  P. Brown,et al.  Single versus Multifraction Stereotactic Radiosurgery for Large Brain Metastases: An International Meta-analysis of 24 Trials. , 2019, International journal of radiation oncology, biology, physics.

[19]  J. Schachter,et al.  Recurrent Pneumonitis in Patients with Melanoma Treated with Immune Checkpoint Inhibitors. , 2019, The oncologist.

[20]  N. Chaput,et al.  Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors. , 2019, European journal of cancer.

[21]  D. Schadendorf,et al.  Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. , 2019, The New England journal of medicine.

[22]  P. Brown,et al.  Treatment of brain metastases with stereotactic radiosurgery and immune checkpoint inhibitors: An international meta-analysis of individual patient data. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[23]  D. Schadendorf,et al.  Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy: Three-Year Follow-up of a Randomized Phase 3 Trial , 2019, JAMA oncology.

[24]  P. Brown,et al.  Preservation of Neurocognitive Function (NCF) with Conformal Avoidance of the Hippocampus during Whole-Brain Radiotherapy (HA-WBRT) for Brain Metastases: Preliminary Results of Phase III Trial NRG Oncology CC001 , 2018, International Journal of Radiation Oncology*Biology*Physics.

[25]  R. Sullivan,et al.  Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis , 2018, JAMA oncology.

[26]  B. Redman,et al.  Prevalence of drug-drug interactions in oncology patients enrolled on National Clinical Trials Network oncology clinical trials , 2018, BMC Cancer.

[27]  D. Schadendorf,et al.  Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[28]  E. Rozeman,et al.  Switch to checkpoint inhibition (CPI) after targeted therapy (TT) at time of progression or during ongoing response: A retrospective analysis of patients with advanced BRAF mutated melanoma. , 2018, Annals of Oncology.

[29]  Correction to Lancet Oncol 2018; 19: 1315-27. , 2018, The Lancet. Oncology.

[30]  Dirk Schadendorf,et al.  Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.

[31]  G. Long,et al.  FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  A. Hauschild,et al.  Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600–Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials , 2018, JAMA oncology.

[33]  J. Utikal,et al.  The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study , 2018, Oncotarget.

[34]  M. Atkins,et al.  Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain , 2018, The New England journal of medicine.

[35]  A. Redig,et al.  Immunotherapy and Symptomatic Radiation Necrosis in Patients With Brain Metastases Treated With Stereotactic Radiation , 2018, JAMA oncology.

[36]  Y. Iwai,et al.  Gamma Knife Radiosurgery for Metastatic Brain Tumors from Malignant Melanomas: A Japanese Multi-Institutional Cooperative and Retrospective Cohort Study (JLGK1501) , 2018, Stereotactic and Functional Neurosurgery.

[37]  N. Khanafer,et al.  Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma , 2018, BMC Cancer.

[38]  L. Zitvogel,et al.  Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[39]  H. Tawbi,et al.  New Era in the Management of Melanoma Brain Metastases. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[40]  J. Wilmott,et al.  Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. , 2018, The Lancet. Oncology.

[41]  M. Vehreschild,et al.  Anti-infective vaccination strategies in patients with hematologic malignancies or solid tumors—Guideline of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[42]  J. Wolchok,et al.  Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab , 2018, Clinical Cancer Research.

[43]  L. Zitvogel,et al.  The intestinal microbiota determines the clinical efficacy of immune checkpoint blockers targeting PD-1/PD-L1 , 2018, Oncoimmunology.

[44]  M. Weichenthal,et al.  Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study. , 2018, European journal of cancer.

[45]  Huanyu Chen,et al.  Patients with melanoma treated with an anti-PD-1 antibody beyond RECIST progression: a US Food and Drug Administration pooled analysis. , 2018, The Lancet. Oncology.

[46]  James R. Anderson,et al.  Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  K. Buder-Bakhaya,et al.  Progression patterns under BRAF inhibitor treatment and treatment beyond progression in patients with metastatic melanoma , 2017, Cancer medicine.

[48]  Douglas B. Johnson,et al.  Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[49]  D. Schadendorf,et al.  Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. , 2017, European journal of cancer.

[50]  D. Schadendorf,et al.  Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials , 2017, JAMA oncology.

[51]  Jeffrey E Gershenwald,et al.  Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[52]  N. Dupin,et al.  BRAF V600 inhibitor discontinuation after complete response in advanced melanoma: a retrospective analysis of 16 patients , 2017, The British journal of dermatology.

[53]  A. Hauschild,et al.  Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017. , 2017, European journal of cancer.

[54]  D. Schadendorf,et al.  Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  Nicholas B. Levine,et al.  Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: a single-centre, randomised, controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[56]  R. Gutzmer,et al.  Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma , 2017, Melanoma research.

[57]  J. Buckner,et al.  Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. , 2017, The Lancet. Oncology.

[58]  Ying Zhang,et al.  Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. , 2017, The Lancet. Oncology.

[59]  Jedd D. Wolchok,et al.  T-cell invigoration to tumour burden ratio associated with anti-PD-1 response , 2017, Nature.

[60]  Bart Neyns,et al.  Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAFV600-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. , 2017, The Lancet. Oncology.

[61]  J. Utikal,et al.  Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. , 2017, European journal of cancer.

[62]  N. Ibrahim,et al.  Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006 , 2017 .

[63]  R. Stupp,et al.  Toxicity of concurrent stereotactic radiotherapy and targeted therapy or immunotherapy: A systematic review. , 2017, Cancer treatment reviews.

[64]  James J. Evans,et al.  Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.

[65]  L. Harrison,et al.  Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[66]  D. Schadendorf,et al.  Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. , 2016, The Lancet. Oncology.

[67]  P. Ascierto,et al.  Cessation of targeted therapy after a complete response in BRAF-mutant advanced melanoma: a case series , 2016, British Journal of Cancer.

[68]  J. Wolchok,et al.  Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[69]  K. Flaherty,et al.  Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[71]  M. Millward,et al.  Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy , 2016, British Journal of Cancer.

[72]  G. Gibney,et al.  Clinical outcomes of melanoma brain metastases treated with stereotactic radiation and anti-PD-1 therapy. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  J. Larkin,et al.  Efficacy and toxicity of rechallenge with combination immune checkpoint blockade in metastatic melanoma: a case series , 2016, Cancer Immunology, Immunotherapy.

[74]  C. Lebbé,et al.  BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma , 2015, Melanoma research.

[75]  A. Hauschild,et al.  Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. , 2015, The Lancet. Oncology.

[76]  K. Flaherty,et al.  Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression. , 2015, European journal of cancer.

[77]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[78]  C. Blank,et al.  Vemurafenib for BRAF V600 mutated advanced melanoma: results of treatment beyond progression. , 2015, European journal of cancer.

[79]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.

[80]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[81]  J. Utikal,et al.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. , 2014, The New England journal of medicine.

[82]  L. Haydu,et al.  The nature and management of metastatic melanoma after progression on BRAF inhibitors: Effects of extended BRAF inhibition , 2014, Cancer.

[83]  R. Sullivan,et al.  Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors , 2014, Cancer.

[84]  P. Ascierto,et al.  Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program , 2014, Cancer investigation.

[85]  Satoshi Suzuki,et al.  Stereotactic radiosurgery for patients with multiple brain metastases (JLGK0901): a multi-institutional prospective observational study. , 2014, The Lancet. Oncology.

[86]  R. Dummer,et al.  Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study. , 2014, European journal of cancer.

[87]  J. Tward,et al.  Radiosurgery for melanoma brain metastases: the impact of hemorrhage on local control. , 2014, Journal of radiosurgery and SBRT.

[88]  S. Pradervand,et al.  Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression , 2013, Clinical Cancer Research.

[89]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[90]  J. Wolchok,et al.  Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. , 2012, The Lancet. Oncology.

[91]  J. Wilmott,et al.  Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.

[92]  M. Mehta,et al.  Leptomeningeal Metastasis: Challenges in Diagnosis and Treatment. , 2011, Current cancer therapy reviews.

[93]  Maria Werner-Wasik,et al.  Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial , 2004, The Lancet.

[94]  C. Dykewicz.  Summary of the Guidelines for Preventing Opportunistic Infections among Hematopoietic Stem Cell Transplant Recipients. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[95]  L Souhami,et al.  Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. , 2000, International journal of radiation oncology, biology, physics.

[96]  M. Mason,et al.  Systemic treatments for metastatic cutaneous melanoma. , 2000, The Cochrane database of systematic reviews.

[97]  R. Gelber,et al.  Value of radiation therapy in the management of patients with cerebral metastases from malignant melanoma. Radiation therapy oncology group brain metastases study I and II , 1980, Cancer.